50 Most Influential Companies of the Year 2021
The concept of regenerative medicine using the body's stem cells and growth factors to repair tissues may become a reality as new basic science works and initial clinical experiences have "teamed up" to develop alternative therapeutic strategies to treat various previously untreatable diseases. Stem cells have tremendous promise to help us understand and treat a range of diseases, injuries, and other health-related conditions. Necessary clinical trials involving stem cells are underway for many different conditions, and researchers continue to explore new avenues using stem cells in medicine.
Some companies worldwide have not limited the use of stem cell therapy to just research and have been using ethically sourced stem cells to treat many health problems, from diseases to cancer. One of the global leaders in stem cell therapy and research is the Global Institute of Stem Cell Therapy and Research (GIOSTAR). GIOSTAR was formed with the vision to provide stem cell-based therapy to aid those suffering from degenerative or genetic diseases around the world. GIOSTAR can treat several devastating immunological disorders and blood-related diseases.
Deven Patel, President, CEO & Co-Founder at GIOSTAR, exclusively spoke to CIO Bulletin. Below is an excerpt of the conversation.
Q. Can you walk us through the company's journey?
Even though we have been in stem cell research for over 20 years, we treat ourselves as a startup because stem cell science is evolving process, and every day we get new insights and reach new heights.
The journey of healing began well before the journey of GIOSTAR in a quest to find cures for incurable diseases. GIOSTAR was destined to happen as it was deep down in the souls of GIOSTAR Dr. AnandSrivastava and me to alleviate sufferings from humanity from a very early age.
We came from very different backgrounds and met at a Hindu Temple in San Diego, California. We founded GIOSTAR literally in the temple, not knowing the journey of healing the world will lead to the world's largest and leading (privately held) stem cell research institute with the most extensive technology portfolio from stem cell science, gene therapy, and cancer research. This, in turn, has put GIOSTAR in the position of taking almost 6 to 12 scientific technology companies public by 2022.
Q. Biomedicine is among the most sophisticated and elegant achievements of modern science. How do you manage parallel and significant strategy, technology, and operations transformations?
Inspiration.Imagination.Innovation. Global Institute of Stem Cell Therapy and Research (GIOSTAR) is ever-vigilant, attentive to the tiniest detail, aware of inconsistencies or discrepancies that give rise to novel ways of describing a condition or considering a problem. True to our scientific rigor, we won't call a cell a stem cell until it meets very stringent criteria — i.e., the ability to self-renew at a single cell level and differentiate into all the major cell types of the organ from which the cell originated. Our science is also driven by "In vivo veritas."
In our therapeutic programs, work never progresses without validation. At GIOSTAR, our scientists follow the leads they uncover in the course of their research. One such foray led to the characterization and isolation of purified human neural stem cells populations, which became the foundation for developing a treatment for neurodegenerative diseases programs.
Q. How do you bridge the gap between academic research and actual technology development?
Academic research is the backbone of technological development. GIOSTAR's Chairman and co-founder, Dr. AnandSrivastava, is an academician. He has been associated with leading universities and research institutes within the USA, has developed several research collaborations with these universities and has extensive research experience in stem cell therapy, documented by several publications in several revered scientific journals.
This academic research helps the GIOSTAR CEO and co-founder Mr. Deven Patel spin out a technology development platform that benefits the masses. He brings a wealth of business development and management experience.
Q. How do you embrace new and more efficient technological developments while maintaining compliance?
We use integrated approaches to characterize specific stem cells. Our scientists use modern scientific techniques such as molecular biology, gene therapy, and genetic engineering to genetically modify cells to study their biological properties and what affects their growth and differentiation. Bioinformatics is used to interrogate cells to uncover similarities and differences and create signature profiles for characterizing.
With the advancement of stem cell science, our range of interests at GIOSTAR expands every day. While our therapeutic programs focus exclusively on transplantation tissue-derived (adult) stem cells and progenitor cells for several degenerative diseases of different organs.
Q. The focus has always been on relevant and actionable skills. And yet, talent recruitment is a major challenge for pharma and biotech/healthcare leaders. How do you make sure you always have the best team possible?
GIOSTAR works with several academic institutions and brings the postgraduates early in the game on board. This way, the best brains train the new talent at GIOSTAR before finishing their degree programs. This creates a very synergistic and collaborative environment at GIOSTAR to keep developing the best talents for the company.
Furthermore, GIOSTAR's team includes international leaders in stem cell research, technologies, healthcare delivery, and hospital administration. GIOSTAR's advisors include an international group of researchers, doctors, and scientists in the field of stem cells and only those with the highest academic, medical, and professional credentials.
Q. Innovative and reliable biomedical/healthcare technology is expensive for obvious reasons. How do you manage to make your services more accessible and affordable?
The GIOSTAR was founded on the basic principles of making this expensive technology available to the masses. To achieve such an uphill task, GIOSTAR works with world governments to help them develop stem cell policies, research, and stem cell transplant programs for entire countries.
We are the only organization in the world in the field of stem cell science that has been able to do this with some degree of success. GIOSTAR is already the official collaborator with the government of Gujarat, India, by setting up a state-of-art stem cell treatment hospital in Surat Civil Hospital for the less fortunate tribal populace in the southern belt of Gujarat suffering from sickle cell anemia.
Q. What does the future hold for GIOSTAR and its clients?
In April 2020, GIOSTAR was one of the first companies in the world to get US FDA approval to treat COVID-19 patients with its proprietary stem cell treatment under the FDA Compassionate Use Program:
See Below USA New Media Coverage Links by ABC NEWS Channel.
With its Post-COVID treatment company going public in 2022, GIOSTAR is also gearing up for several clinical trials for its technology portfolio consisting of Universal Red Blood Cell, Cancer Vaccine, Diabetes, Organ Rejuvenation Stem Cell-Based Skin Care, and Anti-Aging. All six different technology company spin-outs are in the works to go public in 2022.
Dr. Anand Srivastava, Chairman & Co-Founder of GIOSTAR
Dr. Anand Srivastava's success is rooted in his unique background of expertise in stem cell biology, protein biochemistry, molecular biology, immunology, in-utero transplantation of stem cells, tissue targeting, gene therapy, and clinical research. Many scientists can work in a narrowly defined field. However, few have the broad and multidisciplinary experience to conduct clinical research in fields as challenging as Dr. Shrivastava's. His comprehensive expertise is rare in clinical research and perfectly crafted for GIOSTAR's stem cell transplant, cancer, and gene therapy research projects.
MEET THE FOUNDERS
Dr. Anand Srivastava's research work has been presented in various national and international scientific meetings and conferences in India, Japan, Germany, and the USA. His research articles have been published in peer-reviewed medical scientific journals and cited extensively by other scientists. Many scientific fellowships recognized Dr. Anand Srivastava's expertise and scientific achievements. He was twice consecutively bestowed with the highly prestigious and internationally recognized JISTEC award from the Science and Technology Agency, Government of Japan. His research presentation was also awarded the Excellent Presentation Award in the "Meeting of Clinical Chemistry and Medicine," Kyoto, Japan.
He is an expert in genetic engineering research, developmental biology, immunology, and the making of transgenic animals. His extraordinary expertise in searching and characterizing the new genes is ideal for our ongoing projects of developing effective treatments for many degenerative diseases, genetic diseases, and cancer. His extraordinary scientific achievements got his biography included in the "WHO IS WHO IN AMERICA" databank twice, first in 2005 and again in 2010.
Mr. Deven Patel, CEO, President & Co-Founder of GIOSTAR
Under the leadership of Mr. Deven Patel, GIOSTAR is opening dedicated stem cell treatment hospitals worldwide in the USA, India, China, Thailand, Dubai, Philippines, Mexico, Brazil, Sweden, Cambodia, Turkey, Colombia, UAE, Saudi Arabia, and the Bahamas. Honorable Prime Minister of India, Mr. Narendra Modi, inaugurated GIOSTAR's state-of-the-art, world's first, dedicated stem cell treatment hospital in Ahmedabad, Gujarat State, India in July 2011. GIOSTAR is opening five more hospitals in India within the next few years. GIOSTAR, under the leadership of Mr. Patel, is in charge of developing a stem cell transplant program for four different State Governments in India with a total population of approx. 155 million.